20mg Onsior for Dogs
This medication may only be supplied with a valid veterinary prescription issued by your vet. You should only purchase this item if you have or are in the process of arranging such a prescription. See information bar for further details.
Onsior is a new fast-acting pain reliever which concentrates at the site of inflammation. Onsior is available as both an injectable solution and flavoured tablets. Onsior is the first and only coxib NSAID (non-steroidal anti-inflammatory drug) for the relief of pain and inflammation in both cats and dogs.
Onsior targets the pain-causing COX-2 enzymes while sparing the protective actions of COX-1 and is the only coxib licensed for cats as well as dogs. Tissue selectivity is a further benefit of Onsior. The drug travels rapidly through the bloodstream to the site of injury or irritation. It then concentrates at the point of inflammation while exiting the bloodstream very quickly.
Dosed once daily Onsior has an excellent safety profile and fits different administration routes with pain and inflammatory indications. Onsior Flavoured tablets for pain and inflammation related to chronic osteoarthritis in dogs or acute pain and inflammation associated with musculoskeletal disorders in cats.
Onsior are round beige to brown non-divisible tablets with the imprint `NA` on one side and the following imprint on the other side: AK (5 mg tablet) BE (10 mg tablet) CD (20 mg tablet) and BCK (40 mg tablet). Each tablet of Onsior 5mg 10mg 20mg and 40mg respectively contains as active ingredient robenacoxib 5 mg 10 mg 20 mg and 40 mg. Onsior tablets are palatable (flavoured with yeast and artificial beef) and are taken voluntarily by most dogs.
Onsior is a non-steroidal anti-inflammatory drug (NSAID) for use in dogs and cats. Robenacoxib is part of the coxib class of NSAIDs and is recommended for the treatment of pain and inflammation associated with chronic osteoarthritis in dogs. Robenacoxib is a potent and selective inhibitor of the cyclooxygenase 2 enzyme (COX-2). The cyclooxygenase enzyme (COX) is present in two forms. COX-1 is the constitutive form of the enzyme and has protective functions e.g. in the gastrointestinal tract and kidneys. COX-2 is the inducible form of the enzyme and is responsible for the production of mediators including prostaglandin E2 (PGE2) which induce pain inflammation or fever. In an in vitro whole blood assay in dogs robenacoxib was approximately 140-fold selective for COX-2 as compared to COX-1. Robenacoxib produced marked inhibition of COX-2 activity and had no effect on COX-1 activity in dogs at oral doses ranging from 0.5 to 4 mg/kg. Robenacoxib tablets are therefore COX-1 sparing at recommended doses in dogs. Robenacoxib had analgesic and anti-inflammatory actions in an inflammation model in dogs with single oral doses ranging from 0.5 to 8 mg/kg with a rapid onset of action (0.5h). In clinical trials robenacoxib tablets reduced the lameness and inflammation of dogs with chronic osteoarthritis. After oral administration of robenacoxib flavoured tablets at 1 mg/kg without food peak blood concentrations are attained rapidly with a Tmax of 0.5 hour. Co-administration of robenacoxib non-flavoured tablets with food produced no delay in Tmax but slightly lower values for peak blood concentrations. Robenacoxib is highly bound to plasma proteins (>99%) and is extensively metabolised by the liver in dogs. Robenacoxib is cleared rapidly from the blood: after oral administration of the tablets the terminal half-life in blood was 1.2 hour. Robenacoxib persists longer and at higher concentrations at sites of inflammation than in blood. Robenacoxib is excreted predominately via the biliary route (~65%) and the remainder via the kidneys. Repeated oral administration of robenacoxib to dogs at dosages of 2 -10 mg/kg for 6 months produced no change in blood profile with neither accumulation of robenacoxib nor enzyme induction.
Dosage and administration
For oral use. Do not administer with food since clinical trials demonstrated better efficacy of robenacoxib when administered without food or at least 30 minutes before or after a meal. The tablets should not be divided or broken. The recommended dose of robenacoxib is 1 mg/kg body weight with a range of 1-2 mg/kg. Administer once daily at the same time every day according to the table below. Bodyweight (kg) Number of tablets 5mg 10mg 20mg 40mg 2.5 to<5 1 tablet 5 to <10 1 tablet 10 to <20 1 tablet 20 to <40 1 tablet 40 to 80 2 tablets. A clinical response is normally seen within a week. Treatment should be discontinued after 10 days if no clinical improvement is apparent. For long term treatment once clinical response has been observed the dose of Onsior can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic osteoarthritis may vary over time. Regular monitoring should be undertaken by the veterinarian.
Onsior is a POM-V (Prescription-only Medication)